The short- and long-term survival of hyperthermic intraperitoneal chemotherapy (HIPEC) in the advanced gastric cancer with/without peritoneal carcinomatosis: a systematic review and meta-analysis of randomized controlled trials

Deng, Huachu; Li, Baibei; Qin, Xin‐Gan

doi:10.1007/s13304-022-01376-5

Cited by 4 publications

(1 citation statement)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study showed that the 3-year DFS rate of the HIPEC group was better than that of the non-HIPEC group (73.8% vs. 61.2%, P = 0.031); however, a significant difference in the 3-year OS rate was not observed between the two groups (73.9% vs. 77.6%, P = 0.737). The results from another meta-analysis, including 13 studies from 1988 to 2021, showed that there was no significant difference in survival rates between the HIPEC group and the control group at the 1-, 2- and 3-year follow-ups, while a statistically significant overall survival effect was found at the 5-year follow-up (Deng et al 2022 ). Thus, whether prophylactic HIPEC could effectively improve the long-term survival of locally AGC patients still needs further study.…”

Section: Discussionmentioning

confidence: 99%

Hyperthermic intraperitoneal chemotherapy (HIPEC) plus systemic chemotherapy versus systemic chemotherapy alone in locally advanced gastric cancer after D2 radical resection: a randomized-controlled study

Huang

et al. 2023

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Background Currently, there is a lack of an effective strategy for the prevention of peritoneal metastasis (PM) from locally advanced gastric cancer (AGC). This randomized-controlled study aimed to evaluate the outcome of D2 radical resection with hyperthermic intraperitoneal chemotherapy (HIPEC) plus systemic chemotherapy versus systemic chemotherapy alone in locally AGC patients. Methods All enrolled patients were randomly assigned to receive HIPEC plus systemic chemotherapy (HIPEC group) or systemic chemotherapy alone (non-HIPEC group) after radical gastrectomy. HIPEC was performed intraperitoneally with cisplatin (40 mg/m2) within 72 h after surgery, while systemic chemotherapy based on the SOX regimen (S-1 combined with oxaliplatin) was administered 4–6 weeks after radical surgery. Patterns of recurrence, adverse events, 3-year disease-free survival (DFS), and overall survival (OS) were analyzed. Results A total of 134 patients were enrolled in the present study. The 3-year DFS rate was 73.8% in the HIPEC group, which was significantly higher than that in the non-HIPEC group (61.2%, P = 0.031). The 3-year OS rate was 73.9% in the HIPEC group and 77.6% in the non-HIPEC group, with no significant difference (P = 0.737). PM was the most common distant metastasis in both groups. The occurrence rate of PM in the HIPEC group was statistically lower than that in the non-HIPEC group (20.9% vs. 40.3%, P = 0.015). Grade 3 or 4 adverse events occurred in 19 (14.2%) patients, and there was no significant difference between the two groups. Conclusion Radical surgery followed by HIPEC combined with systemic chemotherapy is a safe and feasible strategy for locally AGC patients and could effectively improve DFS and reduce the occurrence of PM. However, more prospective randomized studies with a large sample size are warranted. Trial registration This study was registered with www.medresman.org.cn as ChiCTR2200055966 on 10/12/2016.

show abstract

Section: Discussionmentioning

confidence: 99%

Hyperthermic intraperitoneal chemotherapy (HIPEC) plus systemic chemotherapy versus systemic chemotherapy alone in locally advanced gastric cancer after D2 radical resection: a randomized-controlled study

Huang

et al. 2023

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

Cytoreductive Surgery combined with Hyperthermic Intraperitoneal Chemotherapy and Intraoperative Radiation Therapy in the Management of Gastric Cancer: A 10-Year Single Center Experience

Alaswad,

Arabi,

Alshahrani

et al. 2024

Preprint

View full text Add to dashboard Cite

Background The rationale behind the use of HIPEC involves targeted elimination of microscopic peritoneal metastasis, a common route for GCa dissemination, thereby improving the overall survival and reducing recurrences. Moreover, the reasoning behind the use of IORT is enhanced loco-regional control and, therefore, reducing recurrence rates. Methods From February 2013 to June 2023, all GCa patients who underwent HIPEC plus IORT during surgery were included in this study. Median overall survival (OS) and disease-free (DFS) survival were used to evaluate the efficacy of this treatment strategy amongst GCa patients, along with the rate of occurrence and severity of post-operative complications associated with this treatment strategy. Results The median OS and DFS were 63 and 87 months, respectively. More than one-third of the patients in our cohort did not develop any post-operative complications. In patients who developed post-operative complications, the median number of post-operative complications was 1 (IQR 1–2). Most encountered complications were Clavien-Dindo (CD) grade II complications (33.33%) and no in-hospital mortality was observed. Conclusions This complex, multimodal treatment strategy results in a significantly prolonged OS and DFS when compared to other treatment strategies for gastric cancer patients, with no added morbidity or mortality.

show abstract

Astatine-211 based radionuclide therapy: Current clinical trial landscape

et al. 2023

View full text Add to dashboard Cite

show abstract

The short- and long-term survival of hyperthermic intraperitoneal chemotherapy (HIPEC) in the advanced gastric cancer with/without peritoneal carcinomatosis: a systematic review and meta-analysis of randomized controlled trials

Cited by 4 publications

References 30 publications

Hyperthermic intraperitoneal chemotherapy (HIPEC) plus systemic chemotherapy versus systemic chemotherapy alone in locally advanced gastric cancer after D2 radical resection: a randomized-controlled study

Hyperthermic intraperitoneal chemotherapy (HIPEC) plus systemic chemotherapy versus systemic chemotherapy alone in locally advanced gastric cancer after D2 radical resection: a randomized-controlled study

Cytoreductive Surgery combined with Hyperthermic Intraperitoneal Chemotherapy and Intraoperative Radiation Therapy in the Management of Gastric Cancer: A 10-Year Single Center Experience

Astatine-211 based radionuclide therapy: Current clinical trial landscape

Contact Info

Product

Resources

About